Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Tethys extends the availability of Type 2 diabetes risk test

Tethys Bioscience : 09 June, 2008  (New Product)
Tethys Bioscience has expanded the availability of the company's novel PreDx Diabetes Risk Test, a first-of-its-kind predictive tool that delivers an accurate assessment of an individual's risk of developing Type 2 diabetes within the next five years.
The test is performed exclusively by the Tethys Bioscience Clinical Laboratory on routinely collected blood samples.

The new blood test is designed to help physicians identify patients at highest risk of developing Type 2 diabetes so that they can promote lifestyle changes or initiate treatment plans to prevent or slow progression to Type 2 diabetes. Numerous studies have demonstrated that such interventions can reduce the incidence of new onset diabetes by 30 to 60 percent.

'There are a number of proven methods that clinicians can use to delay or prevent Type 2 diabetes in high-risk people,' said Dr Thomas Buchanan, professor of medicine at the University of Southern California Keck School of Medicine. 'The problem has been the lack of an easy-to-use clinical test to identify the high-risk people. The PreDx Diabetes Risk Test solves that problem. For the first time, clinicians can order a single blood test to assess their patients' diabetes risk and identify those who are in greatest need of diabetes prevention. This is a real paradigm shift.'

Using data generated from thousands of patients who were monitored for up to 17 years, Tethys identified specific proteins and other biomarkers that are most predictive of a person's progression to Type 2 diabetes. Through comprehensive analysis of proteins and integration of multiple risk-defining biomarkers, the company developed a sophisticated test capable of stratifying at-risk individuals. Using a routine blood sample, Tethys provides an individualized risk report that indicates the likelihood of diabetes onset in a patient within the next five years.

'It is already known that we are facing a diabetes epidemic that will only grow worse in the next 10 to 20 years,' said Dr Sean Sullivan, director of Pharmaceutical Outcomes Research and Policy at the University of Washington. 'The ability to identify patients at high risk years ahead of disease diagnosis may allow us to halt diabetes progression, saving lives and helping to maintain or improve the quality of life for our patients, while also reducing the overall expenses associated with the disease.'

'We are very proud to offer this innovative, clinically useful tool that enables physicians to accurately identify those at highest risk of developing Type 2 diabetes long before the disease occurs,' said Mickey Urdea, founder, chairman, and chief executive officer of Tethys Bioscience. 'The PreDx Diabetes Risk Test can help physicians and patients to change the course of diabetes progression. Our mission is to provide tools that will facilitate early intervention in preventable diseases.'

A presentation to be made at the ADA's 68th Scientific Sessions this week supports the accuracy and clinical utility of the PreDx Diabetes Risk Test. The report entitled: 'Training and Validation of a Multimarker Algorithm for the Prediction of Type 2 Diabetes from a 5 Yr Prospective Study of 6,784 Danish People (Inter99) J Kolberg, et al' shows that a simple blood test, based on multiple serum biomarkers, indicates the risk of conversion to Type 2 diabetes, which can provide doctors and patients with objective, quantitative information to intervene and prevent the onset of the disease.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo